Home/Filings/4/0000937889-13-000001
4//SEC Filing

VENROCK ASSOCIATES II LP 4

Accession 0000937889-13-000001

CIK 0001446847other

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 7:46 PM ET

Size

14.4 KB

Accession

0000937889-13-000001

Insider Transaction Report

Form 4
Period: 2013-03-15
Transactions
  • Other

    Class B Common Stock

    2013-03-15920,8322,762,497 total
  • Other

    Class B Common Stock

    2013-03-15639,9011,919,704 total
Holdings
  • Class B Common Stock

    40,000
  • Class B Common Stock

    48,387
  • Class A Common Stock

    2,442
Transactions
  • Other

    Class B Common Stock

    2013-03-15920,8322,762,497 total
  • Other

    Class B Common Stock

    2013-03-15639,9011,919,704 total
Holdings
  • Class B Common Stock

    48,387
  • Class B Common Stock

    40,000
  • Class A Common Stock

    2,442
Transactions
  • Other

    Class B Common Stock

    2013-03-15639,9011,919,704 total
  • Other

    Class B Common Stock

    2013-03-15920,8322,762,497 total
Holdings
  • Class B Common Stock

    48,387
  • Class B Common Stock

    40,000
  • Class A Common Stock

    2,442
Transactions
  • Other

    Class B Common Stock

    2013-03-15920,8322,762,497 total
  • Other

    Class B Common Stock

    2013-03-15639,9011,919,704 total
Holdings
  • Class B Common Stock

    48,387
  • Class B Common Stock

    40,000
  • Class A Common Stock

    2,442
Footnotes (6)
  • [F1]Each share of Class B Common Stock is convertible at any time at the option of the holder thereof into one share of Class A Common Stock and has no expiration date. Each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon (i) any transfer, whether or not for value, (subject to certain exceptions); (ii) in the event of death of the reporting person; or (iii) the earliest of the following (A) the later of (1) the first date on which the number of shares of Class B Common Stock then outstanding represents less than 25% of the number of shares of Class B Common Stock outstanding at the closing of the Issuer's initial public offering, or (2) December 31, 2018, (B) December 31, 2038, or (C) the date agreed to in writing by the holders of at least a majority of then outstanding shares of Class B common stock.
  • [F2]On March 15, 2013, Venrock Associates distributed an aggregate of 639,901 shares of the Class A Common Stock of the issuer to its partners pro rata based on their respective interests in Venrock Associates. After the distribution, Venrock Associates held an aggregate of 1,919,704 shares of Class B Common Stock of the issuer.
  • [F3]On March 15, 2013, Venrock Associates II, L.P. distributed an aggregate of 920,832 shares of the Class A Common Stock of the issuer to its partners pro rata based on their respective interests in Venrock Associates II, L.P. After the distribution, Venrock Associates II, L.P. held an aggregate of 2,762,497 shares of Class B Common Stock of the issuer.
  • [F4]Consists of 48,387 shares of Class B Common Stock of the issuer held by Venrock Entrepreneurs Fund, L.P.
  • [F5]Consists of 40,000 shares of Class B Common Stock of the issuer held by VR Managment, LLC.
  • [F6]Consists of 2,442 shares of Class A Common Stock of the issuer held by VR Managment, LLC.

Issuer

IRONWOOD PHARMACEUTICALS INC

CIK 0001446847

Entity typeother

Related Parties

1
  • filerCIK 0001239243

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 7:46 PM ET
Size
14.4 KB